196 related articles for article (PubMed ID: 21370319)
1. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy.
van der Marel S; Comijn EM; Verspaget HW; van Deventer S; van den Brink GR; Petry H; Hommes DW; Ferreira V
Inflamm Bowel Dis; 2011 Dec; 17(12):2436-42. PubMed ID: 21370319
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
Desrosiers M; Dalkara D
Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
[TBL] [Abstract][Full Text] [Related]
8. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.
Monteilhet V; Saheb S; Boutin S; Leborgne C; Veron P; Montus MF; Moullier P; Benveniste O; Masurier C
Mol Ther; 2011 Nov; 19(11):2084-91. PubMed ID: 21629225
[TBL] [Abstract][Full Text] [Related]
9. AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees.
Calcedo R; Wilson JM
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):79-82. PubMed ID: 27314914
[TBL] [Abstract][Full Text] [Related]
10. Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia.
Pabinger I; Ayash-Rashkovsky M; Escobar M; Konkle BA; Mingot-Castellano ME; Mullins ES; Negrier C; Pan L; Rajavel K; Yan B; Chapin J
Gene Ther; 2024 May; 31(5-6):273-284. PubMed ID: 38355967
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays.
Gorovits B; Fiscella M; Havert M; Koren E; Long B; Milton M; Purushothama S
AAPS J; 2020 Jan; 22(2):24. PubMed ID: 31907680
[TBL] [Abstract][Full Text] [Related]
12. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.
Moskalenko M; Chen L; van Roey M; Donahue BA; Snyder RO; McArthur JG; Patel SD
J Virol; 2000 Feb; 74(4):1761-6. PubMed ID: 10644347
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
[TBL] [Abstract][Full Text] [Related]
14. Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas.
Day TP; Byrne LC; Flannery JG; Schaffer DV
Methods Mol Biol; 2018; 1715():239-249. PubMed ID: 29188518
[TBL] [Abstract][Full Text] [Related]
15. Modifiers of Adeno-Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay.
Krotova K; Aslanidi G
Hum Gene Ther; 2020 Oct; 31(19-20):1124-1131. PubMed ID: 32495655
[TBL] [Abstract][Full Text] [Related]
16. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
Tse LV; Moller-Tank S; Asokan A
Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
[TBL] [Abstract][Full Text] [Related]
18. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.
Scallan CD; Jiang H; Liu T; Patarroyo-White S; Sommer JM; Zhou S; Couto LB; Pierce GF
Blood; 2006 Mar; 107(5):1810-7. PubMed ID: 16249376
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML
Hum Gene Ther; 2006 Apr; 17(4):440-7. PubMed ID: 16610931
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
